 FOSTER CITY, Calif.--BUSINESS WIRE--Geron Corporation Nasdaq: GERN today announced that the first patient has been dosed in IMpactMF, the Phase 3 clinical trial evaluating imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis MF. As the only study in refractory MF with overall survival as the primary endpoint, dosing of the first patient in IMpactMF is an important step in developing imetelstat as a potential treatment for these patients, said Aleksandra Rizo, M 